Share Name Share Symbol Market Type Share ISIN Share Description
Targovax Asa LSE:0RIS London Ordinary Share NO0010689326 TARGOVAX ORD SHS
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.0% 15.98 0.00 0.00 0.00 0.00 0.00 0.00 01:00:00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
- - - - 0

Targovax ASA Appoints Dr Victor Levitsky as Chief Scientific Officer

30/04/2020 6:20am

PR Newswire (US)

Targovax Asa (LSE:0RIS)
Historical Stock Chart

From Feb 2020 to Aug 2020

Click Here for more Targovax Asa Charts.

OSLO, Norway, April 30, 2020 /PRNewswire/ -- Targovax ASA (OSE: TRVX) announces the appointment of Dr Victor Levitsky, MD, PhD as Chief Scientific Officer (CSO). He will play a leading role in driving research strategy and pipeline expansions, particularly the scientific and mechanistic aspects of early clinical work. Dr Levitsky will serve as a member of Targovax's management team.

Dr Levitsky is a seasoned internationally recognized expert in immunology, oncology, T-cell immunotherapy and immuno-oncology with in-depth knowledge of preclinical, translational and early stage clinical drug development. He brings extensive experience in pre-clinical drug development of protein-based biologics and small molecules. Dr Levitsky is a medical doctor with a PhD in Virology and post-doctoral training in tumor biology at Karolinska Institute, Sweden. He spent the first 20 years of his career as an academic research scientist, including Associate Professor positions at the Karolinska Institute in Sweden and the Johns Hopkins University School of Medicine in the US. Before joining Targovax Dr Levitsky served as Tumor Immunology Leader and Senior Principal Scientist with Roche in Zurich, and his most recent position has been VP, Head of Oncology Research at Molecular Partners, Zurich, Switzerland.

Dr Levitsky is the author of numerous scientific publications.

Øystein Soug, CEO, commented:  "It is with great enthusiasm that we welcome Dr Levitsky to Targovax! With his broad and deep oncology experience and with his background as a virologist, he will bring important scientific leadership to Targovax. As we progress towards several important data read-outs and move forward with our pipeline expansion initiatives, Victor will play an instrumental role in shaping the future for Targovax."

Dr Levitsky added: "I am very excited to be joining Targovax at what is clearly an important stage for the company. The oncolytic virus and mutant RAS technology platforms have clear potential to benefit cancer patients through current and multiple novel strategies, and I look forward to joining the strong team at Targovax to help build the scientific framework for bringing these promising products to patients." 

Dr Levitsky will commence as CSO on 4th May.

For further information, please contact:
Renate Birkeli, Investor Relations
Phone: +47-922-61-624

Media and IR enquires:
Andreas Tinglum - Corporate Communications (Norway)
Phone: +47-9300-1773

This information was brought to you by Cision,c3101140


Copyright 2020 PR Newswire

1 Year Targovax Asa Chart

1 Year Targovax Asa Chart

1 Month Targovax Asa Chart

1 Month Targovax Asa Chart
ADVFN Advertorial
Your Recent History
Targovax A..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V:gb D:20200811 01:59:13